Literature DB >> 21048909

Targeted Therapy of Breast Cancer - New Insights and Perspectives.

Joachim Bischoff1.   

Abstract

Year:  2008        PMID： 21048909      PMCID： PMC2931026          DOI： 10.1159/000177226

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  17 in total

1.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.

Authors:  Suling Liu; Gabriela Dontu; Ilia D Mantle; Shivani Patel; Nam-shik Ahn; Kyle W Jackson; Prerna Suri; Max S Wicha
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 2.  Development of new predictive markers for endocrine therapy and resistance in breast cancer.

Authors:  Katrine L Henriksen; Katrine Sonne-Hansen; Tove Kirkegaard; Thomas Frogne; Anne E Lykkesfeldt
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

3.  Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

Authors:  Rita Nahta; Linda X H Yuan; Yi Du; Francisco J Esteva
Journal:  Mol Cancer Ther       Date:  2007-02       Impact factor: 6.261

4.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

Review 5.  Mammalian target of rapamycin as a therapeutic target in oncology.

Authors:  Robert T Abraham; Christina H Eng
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

6.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Authors:  Harold J Burstein; Anthony D Elias; Hope S Rugo; Melody A Cobleigh; Antonio C Wolff; Peter D Eisenberg; Mary Lehman; Bonne J Adams; Carlo L Bello; Samuel E DePrimo; Charles M Baum; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-03-17       Impact factor: 44.544

Review 7.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

8.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Authors:  Xiaoxian Li; Michael T Lewis; Jian Huang; Carolina Gutierrez; C Kent Osborne; Meng-Fen Wu; Susan G Hilsenbeck; Anne Pavlick; Xiaomei Zhang; Gary C Chamness; Helen Wong; Jeffrey Rosen; Jenny C Chang
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

9.  Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Authors:  Gottfried E Konecny; Y Gloria Meng; Michael Untch; He-Jing Wang; Ingo Bauerfeind; Melinda Epstein; Petra Stieber; Jean-Michel Vernes; Johnny Gutierrez; Kyu Hong; Malgorzata Beryt; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

10.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Authors:  David Cameron; Michelle Casey; Michael Press; Deborah Lindquist; Tadeusz Pienkowski; C Gilles Romieu; Stephen Chan; Agnieszka Jagiello-Gruszfeld; Bella Kaufman; John Crown; Arlene Chan; Mario Campone; Patrice Viens; Neville Davidson; Vera Gorbounova; Johannes Isaac Raats; Dimosthenis Skarlos; Beth Newstat; Debasish Roychowdhury; Paolo Paoletti; Cristina Oliva; Stephen Rubin; Steven Stein; Charles E Geyer
Journal:  Breast Cancer Res Treat       Date:  2008-01-11       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.